The seasoned approach
The benzodiazepine question in chronic anxiety, especially in the longevity-psychiatry frame. The discipline is to recognize the legitimate short-term utility, the substantial long-term cost, and the slow respectful work of tapering chronic users while building durable alternatives.
Layer 1 — First — the appropriate use
Short-term acute use (days to weeks) for acute anxiety, perioperative anxiety, brief crisis stabilization, alcohol withdrawal, status epilepticus. The pharmacology is real and the short-term clinical use is appropriate when matched to the clinical scenario. The problem is not benzodiazepines; the problem is chronic indefinite use without reassessment.
Layer 2 — The chronic-use problem
Chronic benzodiazepine use in adults over 50 is associated with elevated dementia risk in observational studies (HR roughly 1.3–1.5, with stronger associations for longer-duration use and higher cumulative dose). Fall risk and fracture risk are substantially elevated in older adults. Memory consolidation effects produce ongoing low-grade cognitive impact even in chronically-tolerant users. Tolerance and dependence emerge with continued use; abrupt discontinuation produces severe withdrawal syndromes.
Layer 3 — Tapering as the standard of care
Most patients on chronic benzodiazepines should be tapered, not maintained indefinitely. The taper is slow (months, not weeks), respectful (the patient's experience matters), layered with alternatives (treat the underlying anxiety properly), and supported (regular visits, validation, problem-solving). The taper that fails is usually the taper that was too fast or done without adequate alternative treatment in place.
Layer 4 — The taper protocol
Convert to equivalent diazepam dose if not already on long-acting agent (long half-life smooths the taper). Reduce by 10–25% of current dose every 2–4 weeks; slower in late stages of taper. The last 25% of taper is often slower than earlier reductions. Use diazepam, clonazepam, or lorazepam as the taper vehicle; alprazolam is harder to taper due to short half-life. Consider the patient's preference and prior history.
Layer 5 — Alternative treatment during and after taper
SSRIs/SNRIs as foundation for chronic anxiety. Buspirone, pregabalin, hydroxyzine, gabapentin for adjunctive anxiety treatment. CBT for behavioral foundation. HRV biofeedback and polyvagal interventions (Stage 11.3) for autonomic substrate. Sleep treatment (Stage 4/12) for sleep-related residual symptoms. The taper succeeds when the alternative treatment is in place; the taper fails when nothing replaces what was being suppressed.
Layer 6 — When chronic maintenance is appropriate
Selected patients with refractory anxiety where all alternatives have been adequately tried and failed, where the functional benefit clearly outweighs the cumulative cost, and where the conversation about long-term risks has been thorough. This is a small subset; most patients on chronic benzodiazepines have not had adequate alternatives tried and would benefit from taper with proper alternative treatment.
Special situations
- Patient over 65 on chronic benzodiazepine: Priority taper given fall risk, dementia association, and metabolic accumulation. Slower taper than younger patients; close cognitive and gait monitoring. The cumulative cost is high; the cost of taper with proper support is low.
- Patient with prominent panic disorder on chronic lorazepam: Optimize SSRI/SNRI first; ensure adequate dose and duration before initiating taper. CBT for panic specifically. Slow taper with rescue dose available for breakthrough anxiety during transition.
- Patient with comorbid alcohol use disorder: Benzodiazepines in this population add substantial overdose risk and reinforce the addiction substrate. Taper is part of comprehensive AUD treatment; do not maintain chronic benzodiazepines in active alcohol use disorder absent extraordinary circumstances.
- Patient adamantly refusing taper: Document the conversation, the rationale, the alternatives offered, and the patient's informed decision. Continue to engage; tapers that fail today may succeed in 1–2 years with continued conversation and trust-building. The patient's autonomy is real, and the clinical relationship matters more than winning the argument.
Generally avoid
- Abrupt discontinuation of chronic benzodiazepines — produces severe withdrawal including seizure risk, and reinforces patient distrust of taper attempts. Taper, not stop.
- Inheriting chronic benzodiazepine prescriptions without reassessment — the patient who has been on lorazepam for fifteen years deserves the conversation about what alternative treatment would look like and whether taper is appropriate. Do not just continue the prescription.
- Prescribing chronic benzodiazepines for sleep without robust alternatives tried — chronic Z-drugs and benzodiazepines for sleep in older adults are particularly problematic; CBT-I, trazodone, low-dose doxepin, DORAs (Stage 4) are preferred.
- Adding benzodiazepines to chronic opioid prescriptions — the combination substantially elevates overdose mortality. The CDC guidance is clear; the practice is still common; it should not be.
The chief-resident note: Most chronic benzodiazepine prescriptions in psychiatric care started with reasonable intent and continued because no one revisited the decision. The audit-and-taper work is some of the highest-leverage longevity-psychiatry care available, and it produces measurable cognitive, functional, and safety benefits in the populations most likely to be on chronic benzodiazepines. Build the practice to support tapers — schedule the time, treat the alternatives properly, validate the patient's experience, and persist through the slow work. Most chronic benzodiazepine users can be successfully tapered with adequate support and proper alternative treatment.
Benzodiazepines occupy a complicated place in chronic anxiety treatment. The pharmacology is real — GABA-A potentiation produces reliable acute anxiolysis and sedation — and short-term clinical use is genuinely appropriate for acute scenarios. The longevity-psychiatry concern is the chronic use that often follows: indefinite prescription without reassessment, accumulating cognitive and functional cost, and the dependency that makes taper progressively difficult. The discipline is to recognize the short-term utility, treat the long-term cost as real, and engage chronic users in the slow respectful work of tapering with adequate alternative treatment in place.
The cognitive evidence has matured considerably. Observational studies link chronic benzodiazepine use to elevated dementia risk with hazard ratios in the 1.3–1.5 range, with stronger associations for longer-duration use and higher cumulative dose. The studies have limitations — confounding by indication is non-trivial, since anxiety itself is a dementia risk factor — but the consistency of the signal across cohorts, the mechanistic plausibility (GABA-mediated effects, memory consolidation effects, sedation), and the accompanying functional concerns (falls, fractures, motor vehicle accidents, daytime cognitive function) make the cumulative cost real. The patient on chronic benzodiazepines for years is bearing a cost they may not feel acutely.
Fall risk in older adults is the most immediate functional concern. Benzodiazepines substantially elevate fall risk and fracture risk in older adults, with effects detectable at clinically standard doses and across the benzodiazepine class. A single hip fracture in an older adult produces measurable trajectory loss; the medication that produces fall risk should be evaluated against the benefit it provides, and most chronic benzodiazepine prescriptions in older adults will not survive that evaluation when adequate alternatives are considered.
The tapering work is the clinical discipline. Most patients on chronic benzodiazepines can be successfully tapered with adequate support and proper alternative treatment in place. The taper is slow (months), respectful (the patient's experience matters), layered with alternatives (treat the underlying anxiety properly), and supported (regular visits, validation, problem-solving). The taper that fails is usually one that was too fast, or one that did not address the underlying anxiety with adequate alternative treatment. The taper that succeeds rests on the prescriber's commitment to the patient's long-term outcome over their short-term comfort.
The conversion-to-long-acting and gradual-reduction protocol. Convert short-half-life benzodiazepines (alprazolam, lorazepam) to diazepam equivalents for smoother taper; diazepam's long half-life produces more even serum concentrations during reduction. Reduce by 10–25% of current dose every 2–4 weeks, slower in late stages. The last 25% of taper is often the slowest and most challenging; expect to spend months on that portion alone. Use validated equivalence tables; rotate the dose-adjustment approach based on the patient's experience. The taper is a clinical relationship that requires ongoing dialogue, not a protocol executed in isolation.
Alternative treatment during and after taper is non-optional. The taper succeeds when SSRIs/SNRIs are optimized, buspirone or pregabalin augmentation is added where appropriate, CBT addresses the cognitive-behavioral foundation, HRV biofeedback and polyvagal interventions address the autonomic substrate, sleep is properly treated, and lifestyle factors are addressed. The taper fails when the underlying anxiety is left untreated and the patient experiences breakthrough symptoms that cannot be managed without the benzodiazepine. The longevity-psychiatry discipline is to recognize that chronic benzodiazepine use is most often a marker of inadequate alternative treatment, and that the work of building adequate alternatives is the work that allows the taper to succeed.